Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138241693> ?p ?o ?g. }
- W3138241693 endingPage "1483" @default.
- W3138241693 startingPage "1483" @default.
- W3138241693 abstract "Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent castration resistance status (CRPC) is commonly developed. The expression of androgen receptor (AR) alternative splicing isoforms (AR-V7 and AR-V9) has been associated to CRPC. However, resistance mechanisms to novel NHAs are not yet well understood. Androgen-dependent PCa cell lines were used to generate resistant models to ADT only or in combination with Abiraterone and/or Enzalutamide (concomitant models). Functional and genetic analyses were performed for each resistance model by real-time cell monitoring assays, flow cytometry and RT-qPCR. In androgen-dependent PCa cells, the administration of Abiraterone and/or Enzalutamide as first-line treatment involved a critical inhibition of AR activity associated with a significant cell growth inhibition. Genetic analyses on ADT-resistant PCa cell lines showed that the CRPC phenotype was accompanied by overexpression of AR full-length and AR target genes, but not necessarily AR-V7 and/or AR-V9 isoforms. These ADT resistant cell lines showed higher proliferation rates, migration and invasion abilities. Importantly, ADT resistance induced cross-resistance to Abiraterone and/or Enzalutamide. Similarly, concomitant models possessed an elevated expression of AR full-length and proliferation rates and acquired cross-resistance to its alternative NHA as second-line treatment." @default.
- W3138241693 created "2021-03-29" @default.
- W3138241693 creator A5000076780 @default.
- W3138241693 creator A5000317094 @default.
- W3138241693 creator A5000593540 @default.
- W3138241693 creator A5031849720 @default.
- W3138241693 creator A5043028574 @default.
- W3138241693 creator A5045332186 @default.
- W3138241693 creator A5051876862 @default.
- W3138241693 creator A5052252828 @default.
- W3138241693 creator A5070274823 @default.
- W3138241693 creator A5074919227 @default.
- W3138241693 creator A5081974105 @default.
- W3138241693 creator A5090190690 @default.
- W3138241693 date "2021-03-23" @default.
- W3138241693 modified "2023-10-10" @default.
- W3138241693 title "Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation" @default.
- W3138241693 cites W1512914561 @default.
- W3138241693 cites W1634543743 @default.
- W3138241693 cites W1844925317 @default.
- W3138241693 cites W1967684037 @default.
- W3138241693 cites W1995039837 @default.
- W3138241693 cites W1996389184 @default.
- W3138241693 cites W1996739656 @default.
- W3138241693 cites W1999343166 @default.
- W3138241693 cites W2003955264 @default.
- W3138241693 cites W2015582646 @default.
- W3138241693 cites W2035380640 @default.
- W3138241693 cites W2041034966 @default.
- W3138241693 cites W2064360128 @default.
- W3138241693 cites W2068905761 @default.
- W3138241693 cites W2068927098 @default.
- W3138241693 cites W2077301757 @default.
- W3138241693 cites W2081365151 @default.
- W3138241693 cites W2110534364 @default.
- W3138241693 cites W2110841612 @default.
- W3138241693 cites W2112730174 @default.
- W3138241693 cites W2118564089 @default.
- W3138241693 cites W2119504728 @default.
- W3138241693 cites W2121023961 @default.
- W3138241693 cites W2133328863 @default.
- W3138241693 cites W2138504446 @default.
- W3138241693 cites W2148180201 @default.
- W3138241693 cites W2148643283 @default.
- W3138241693 cites W2156923287 @default.
- W3138241693 cites W2160844431 @default.
- W3138241693 cites W2161987148 @default.
- W3138241693 cites W2224112866 @default.
- W3138241693 cites W2340799873 @default.
- W3138241693 cites W2483037648 @default.
- W3138241693 cites W2589995858 @default.
- W3138241693 cites W2597130646 @default.
- W3138241693 cites W2611741716 @default.
- W3138241693 cites W2768924090 @default.
- W3138241693 cites W2791152362 @default.
- W3138241693 cites W2799423581 @default.
- W3138241693 cites W2806665283 @default.
- W3138241693 cites W2883077013 @default.
- W3138241693 cites W2890018574 @default.
- W3138241693 cites W2912662942 @default.
- W3138241693 cites W2918289493 @default.
- W3138241693 cites W2947158345 @default.
- W3138241693 cites W3112873894 @default.
- W3138241693 doi "https://doi.org/10.3390/cancers13061483" @default.
- W3138241693 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8004828" @default.
- W3138241693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33807106" @default.
- W3138241693 hasPublicationYear "2021" @default.
- W3138241693 type Work @default.
- W3138241693 sameAs 3138241693 @default.
- W3138241693 citedByCount "16" @default.
- W3138241693 countsByYear W31382416932021 @default.
- W3138241693 countsByYear W31382416932022 @default.
- W3138241693 countsByYear W31382416932023 @default.
- W3138241693 crossrefType "journal-article" @default.
- W3138241693 hasAuthorship W3138241693A5000076780 @default.
- W3138241693 hasAuthorship W3138241693A5000317094 @default.
- W3138241693 hasAuthorship W3138241693A5000593540 @default.
- W3138241693 hasAuthorship W3138241693A5031849720 @default.
- W3138241693 hasAuthorship W3138241693A5043028574 @default.
- W3138241693 hasAuthorship W3138241693A5045332186 @default.
- W3138241693 hasAuthorship W3138241693A5051876862 @default.
- W3138241693 hasAuthorship W3138241693A5052252828 @default.
- W3138241693 hasAuthorship W3138241693A5070274823 @default.
- W3138241693 hasAuthorship W3138241693A5074919227 @default.
- W3138241693 hasAuthorship W3138241693A5081974105 @default.
- W3138241693 hasAuthorship W3138241693A5090190690 @default.
- W3138241693 hasBestOaLocation W31382416931 @default.
- W3138241693 hasConcept C121608353 @default.
- W3138241693 hasConcept C126322002 @default.
- W3138241693 hasConcept C143998085 @default.
- W3138241693 hasConcept C2776421732 @default.
- W3138241693 hasConcept C2776551883 @default.
- W3138241693 hasConcept C2777899217 @default.
- W3138241693 hasConcept C2777911890 @default.
- W3138241693 hasConcept C2780192828 @default.
- W3138241693 hasConcept C502942594 @default.
- W3138241693 hasConcept C61367390 @default.
- W3138241693 hasConcept C71315377 @default.